Veranova, a leader in the development and manufacture of specialty and complex active pharmaceutical ingredients (API) for the pharmaceutical and biotech sectors, announced that a routine current Good Manufacturing Practice (cGMP) surveillance inspection of Veranova’s Devens, Massachusetts site, completed by the FDA New England District on July 31, 2025, concluded without any Form 483s and with a “No Action Indicated” (NAI) classification.  This FDA inspection outcome continues Veranova’s str...